Acumen Pharmaceuticals, Inc.ABOSNASDAQ
Loading
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +10.79% | +3.63% | +1.19% | +0.82% | +0.82% |
| Weighted Average Shares Diluted Growth | +10.79% | +3.45% | +1.19% | +0.82% | +0.82% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | -100.00% | +98.94% | +197.17% | +0.00% |
| Inventory Growth | +113.43% | +0.00% | +0.00% | +0.00% | -100.00% |
| Asset Growth | -6.77% | -22.94% | -32.06% | -40.50% | -46.73% |
| Book Value per Share Growth | -30.05% | -34.28% | -41.35% | -52.40% | -57.45% |
| Debt Growth | +1499300.00% | +4.27% | +3.68% | +6.69% | +2.83% |
| R&D Expense Growth | +143.73% | +160.05% | +102.96% | +90.06% | -19.37% |
| SG&A Expenses Growth | +3.25% | -2.44% | -4.15% | -4.60% | -9.43% |